First results of a first-in-man proof of concept study of an anti-CD4mAb-fragment for the imaging of chronic inflammation in patients with active rheumatoid arthritis

被引：0
|
作者：
Siegert, J. [1 ]
Brecht, B. [1 ]
Hesse, S. [2 ]
Schindler, C. [1 ]
Pigla, U. [3 ]
Sabri, O. [2 ]
Kirch, W. [1 ]
机构：
[1] Tech Univ Dresden, Fac Med, Inst Clin Pharmacol, Dresden, Germany
[2] Univ Leipzig, Klin & Poliklin Nucl Med, Leipzig, Germany
[3] Biotectid GmbH, Leipzig, Germany
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2007年 / 101卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
C-11
引用
收藏
页码：369 / 369
页数：1
相关论文
共 36 条
  • [1] Results of an adaptive first in man proof of concept study (Bayesian approach) for imaging chronic inflammation in patients with active rheumatoid arthritis with an anti-CD4mAB-Fragment (EP 1645)
    Siegert, Joachim
    Hesse, Swen
    Schindler, Christoph
    Idelevich, Evgeny
    Brecht, Beate
    Bocking, Wolfgang
    Laub, Rudiger
    Pigla, Ullrich
    Sabri, Osama
    Kirch, Wilhelm
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1119 - 1119
  • [2] EP 1645-AN ANTI-CD4MAB-FRAGMENT - FOR IMAGING CHRONIC INFLAMMATION IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS - SAFETY EVALUATION OF CARDIOVASCULAR DATA FROM A FIRST IN MAN BAYESIAN APPROACH CLINICAL TRIAL
    Siegert, Joachim
    Hesse, Swen
    Schindler, Christoph
    Idelevich, Evgeny
    Hillger, Christiane
    Steinhoff, Karen G.
    Wirkner, Kerstin
    Pigla, Ullrich
    Sabri, Osama
    Kirch, Wilhelm
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1125 - 1125
  • [3] Efficacy Data of an Adaptive 1st in Man Study (Bayesian Approach) for Imaging Chronic Inflammation in Patients with Active Rheumatoid Arthritis with an Anti-Cd4mab-Fragment (Ep 1645)
    Siegert, Joachim
    Hesse, Swen
    Schindler, Christoph
    Idelevich, Evgeny
    Brecht, Beate
    Wirkner, Kerstin
    Laub, Ruediger
    Pigla, Ullrich
    Sabri, Osama
    Kirch, Wilhelm
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 104 (06) : 524 - 524
  • [4] Imaging of chronic inflammation with an anti-CD4MAB fragment (EP 1645) - results of an adaptive study (Bayesian approach) in patients with active rheumatoid arthritis
    Siegert, J.
    Hesse, S.
    Schindler, C.
    Idelevich, E.
    Brecht, B.
    Laub, R.
    Pigla, U.
    Sabri, O.
    Kirch, W.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2009, 379 : 92 - 93
  • [5] Visualizing inflammation activity in rheumatoid arthritis with Tc-99m Anti-CD4-mAb fragment scintigraphy - First results of a proof of principle study
    Steinhoff, K. G.
    Pierer, M.
    Siegert, J.
    Pigla, U.
    Laub, R.
    Hesse, S.
    Seidel, W.
    Sorger, D.
    Seese, A.
    Kuenstler, J. U.
    Pietzsch, J.
    Emmrich, F.
    Sabri, O.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S210 - S210
  • [6] Visualizing inflammation activity in rheumatoid arthritis with Tc-99 m Anti-CD4-mAb fragment scintigraphy
    Steinhoff, K.
    Pierer, M.
    Siegert, J.
    Pigla, U.
    Laub, R.
    Hesse, S.
    Seidel, W.
    Sorger, D.
    Seese, A.
    Kuenstler, J. U.
    Pietzsch, H. J.
    Lincke, T.
    Rullmann, M.
    Emmrich, F.
    Sabri, O.
    NUCLEAR MEDICINE AND BIOLOGY, 2014, 41 (04) : 350 - 354
  • [7] AFFINITY AND POTENCY OF THE ANTI-NKG2A MAB NNC141-0100: IMPLICATIONS FOR MABEL AND DOSING IN THE FIRST-IN-MAN TRIAL IN RHEUMATOID ARTHRITIS
    Alifrangis, L.
    Andre, P.
    Pascal, V.
    Bonnet, E.
    Radzikowski, L.
    Petersen, M. B.
    Blery, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 191 - 191
  • [8] Molecular imaging in rheumatology: Tc-99 labeled anti CD4 mAb fragment scintigraphy for the assessment of synovitis 2 in patients with rheumatoid arthritis
    Pierer, Matthias
    Hesse, Swen
    Baerwald, Christoph
    Linke, Thomas
    Aringer, Michael
    Seidel, Wolfram
    Sabri, Osama
    Kuenstler, Jens-Uwe
    Pietzsch, Jens
    Pigla, Ullrich
    Laub, Ruediger
    Ernmrich, Frank
    Siegert, Jens
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S699 - S699
  • [9] FIRST-IN-PATIENT STUDY OF NAMILUMAB, AN ANTI-GM-CSF MONOCLONAL ANTIBODY, IN ACTIVE RHEUMATOID ARTHRITIS: RESULTS OF THE PRIORA PHASE IB STUDY
    Huizinga, T. W. J.
    Batalov, A.
    Yablanski, K.
    Stoilov, R.
    Lloyd, E.
    Wagner, T.
    Saurigny, D.
    Souberbielle, B.
    Esfandiari, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 733 - 733
  • [10] First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127-T regulatory cells
    Trzonkowski, Piotr
    Bieniaszewska, Maria
    Juscinska, Jolanta
    Dobyszuk, Anita
    Krzystyniak, Adam
    Marek, Natalia
    Mysliwska, Jolanta
    Hellmann, Andrzej
    CLINICAL IMMUNOLOGY, 2009, 133 (01) : 22 - 26
1234